GRAIL to Present at the BofA Securities 2026 Health Care Conference
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:40 a.m. PT. Live and replay webcasts will be available via the investor relations site and archived for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – GRAL
In the May 1 session, GRAL declined 0.77%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Earnings date notice | Neutral | -3.7% | Announced timing of Q1 2026 results release and webcast details. |
| Apr 21 | Clinical data update | Positive | +1.8% | Planned late-breaking NHS-Galleri and PATHFINDER 2 results at ASCO 2026. |
| Apr 07 | Commercial integration | Positive | +3.3% | Integration of Galleri test ordering/results into Epic EHR for ~450 systems. |
| Apr 01 | Commercial partnership | Positive | +3.7% | Partnership with Superpower to offer Galleri through a preventative platform. |
| Mar 12 | Management transition | Negative | -2.9% | CEO retirement and appointment of Joshua Ofman as successor effective June 1. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows positive price reactions to commercial and clinical updates, while management changes and scheduling/earnings-related notices have coincided with modest declines.
Over the last six weeks, GRAL has issued a mix of clinical, commercial, and governance updates. Commercial and partnership news around the Galleri test on Apr 1 and Apr 7, and ASCO data presentation news on Apr 21, were followed by gains between about 1–4%. In contrast, the CEO transition announcement on Mar 12 and the upcoming Q1 2026 results notice on Apr 22 saw declines of about 3%. Today’s conference appearance fits the pattern of non-fundamental, visibility-oriented announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-bofa-securities-2026-health-care-conference-302759240.html
SOURCE GRAIL, Inc.